SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors
Published in
Therapeutic Advances in Medical Oncology, November 2024
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2024.
All research outputs
#19,558,973
of 28,354,110 outputs
Outputs from Therapeutic Advances in Medical Oncology
#601
of 1,017 outputs
Outputs of similar age
#176,734
of 342,318 outputs
Outputs of similar age from Therapeutic Advances in Medical Oncology
#24
of 62 outputs
Altmetric has tracked 28,354,110 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,017 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,318 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.